Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Página do item simplificado
dc.contributor.authorAguiar, Pedro Nazareth, Jr. [UNIFESP]
dc.contributor.authorMuniz, Thiago Pimentel [UNIFESP]
dc.contributor.authorMiranda, Raelson Rodrigues [UNIFESP]
dc.contributor.authorTadokoro, Hakaru [UNIFESP]
dc.contributor.authorForones, Nora Manoukian [UNIFESP]
dc.contributor.authorMonteiro, Ines-de-Paula
dc.contributor.authorCastelo-Branco, Pedro
dc.contributor.authorJanjigian, Yelena Y.
dc.contributor.authorde Mello, Ramon Andrade
dc.date.accessioned2019-01-21T10:30:07Z
dc.date.available2019-01-21T10:30:07Z
dc.date.issued2016
dc.description.abstractIn this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneousen
dc.description.abstracttherefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.en
dc.description.affiliationDivision of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil
dc.description.affiliationDepartment of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
dc.description.affiliationDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
dc.description.affiliationDepartment of Biomedical Sciences & Medicine, Division of Oncology, University of Algarve, Faro, Portugal
dc.description.affiliationClinical Research Center & Department of Medical Oncology, Centro Oncológico São Mateus, Ceará Cancer Institute, Rua Papi Junior 1222, Rodolfo Teófilo, CEP 60430-235, Fortaleza-CE, Brazil
dc.description.affiliationUnifespDivision of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipPierre-Fabre
dc.format.extent839-854
dc.identifierhttps://doi.org/10.2217/fon.15.348
dc.identifier.citationFuture Oncology. London, v. 12, n. 6, p. 839-854, 2016.
dc.identifier.doi10.2217/fon.15.348
dc.identifier.issn1479-6694
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49598
dc.identifier.wosWOS:000371064800012
dc.language.isoeng
dc.publisherFuture medicine ltd
dc.relation.ispartofFuture Oncology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCurrent Advancesen
dc.subjectGastric Canceren
dc.subjectGastric Cancer Therapyen
dc.subjectPatient Careen
dc.subjectTargeted TherapyAdvanced Esophagogastric Canceren
dc.subjectMulticenter Phase-Iien
dc.subjectGastroesophageal Junction Canceren
dc.subjectEndothelial Growth-Factoren
dc.subjectDouble-Blinden
dc.subjectOpen-Labelen
dc.subject1st-Line Treatmenten
dc.subjectRandomized Phase-2en
dc.subjectNext-Generationen
dc.subjectPlus Paclitaxelen
dc.titleCurrent advances in targeted therapies for metastatic gastric cancer: improving patient careen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Coleções
EPM - Artigos